Bioavailability of Quinidine in Congestive Heart Failure

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1981 Jun 1

PMID 7272173

Citations 7

Authors

C T Ueda

B S Dzindzio

Affiliations

Soon will be listed here.

Abstract

1 The oral bioavailability of quinidine was evaluated in eight patients with moderate to severe congestive heart failure. Each patient was given a 400 mg dose of quinidine gluconate by intravenous infusion and orally in solution. Serial plasma samples and total urine for drug analysis were collected for 24 and 48 h after drug administration, respectively. 2 When compared to control cardiac patients, the rate of quinidine absorption was slower in the heart failure patients. The mean value for the apparent absorption half-life and time to achieve peak plasma quinidine concentration was 38 +/- 18 min and 2.4 +/- 1.5 h respectively. The corresponding values observed in the control subjects were 18 +/- 6 min and 1.0 +/- 0.6 h. 3 The extent of quinidine absorption when evaluated by the AUC and urinary excretion methods was about 72% of the administered dose in the congestive heart failure patients. This value was similar to the extent of quinidine absorption (approximately 73%) observed in the control subjects. 5 When compared with non-heart failure cardiac patients, the results of this study suggest that patients with congestive heart failure may require smaller oral quinidine dosages to achieve therapeutic drug concentrations in the plasma or serum.

Citing Articles

The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Mangoni A, Jarmuzewska E Br J Clin Pharmacol. 2018; 85(1):20-36.

PMID: 30194701 PMC: 6303202. DOI: 10.1111/bcp.13760.

Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.

Yamaura S, Fukao M, Ishida K, Taguchi M, Hashimoto Y Eur J Drug Metab Pharmacokinet. 2013; 39(1):53-9.

PMID: 23739952 DOI: 10.1007/s13318-013-0140-2.

Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Deneer V, van Hemel N Drugs Aging. 2011; 28(8):617-33.

PMID: 21812498 DOI: 10.2165/11591680-000000000-00000.

Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.

Jaillon P, Poirier J, Lecocq B, Jarreau C, PAYS M, Richard M Eur J Drug Metab Pharmacokinet. 1986; 11(3):233-8.

PMID: 3816879 DOI: 10.1007/BF03189851.

The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.

Dickstein K, Till A, Aarsland T, Tjelta K, Abrahamsen A, Kristianson K Br J Clin Pharmacol. 1987; 23(4):403-10.

PMID: 3034316 PMC: 1386089. DOI: 10.1111/j.1365-2125.1987.tb03069.x.

References

BOYES R, ADAMS H, Duce B . Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs. J Pharmacol Exp Ther. 1970; 174(1):1-8. View

Anderson K, BRETTELL H, AIKAWA J . C14-labeled hydrochlorothiazide in human beings. Arch Intern Med. 1961; 107:736-42. DOI: 10.1001/archinte.1961.03620050102011. View

Stenson R, Constantino R, Harrison D . Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation. 1971; 43(2):205-11. DOI: 10.1161/01.cir.43.2.205. View

Bellet S, ROMAN L, Boza A . Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency. Am J Cardiol. 1971; 27(4):368-71. DOI: 10.1016/0002-9149(71)90432-2. View

Nies A, Evans G, SHAND D . The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol. J Pharmacol Exp Ther. 1973; 184(3):716-20. View

Thomson P, Melmon K, Richardson J, Cohn K, Steinbrunn W, Cudihee R . Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973; 78(4):499-508. DOI: 10.7326/0003-4819-78-4-499. View

Crouthamel W . Letter: Elimination of quinidine in congestive heart failure. N Engl J Med. 1974; 290(24):1379-80. DOI: 10.1056/NEJM197406132902413. View

Tilstone W, Dargie H, Dargie E, MORGAN H, Kennedy A . Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther. 1974; 16(2):322-9. DOI: 10.1002/cpt1974162322. View

Boxenbaum H, RIEGELMAN S, Elashoff R . Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974; 2(2):123-48. DOI: 10.1007/BF01061504. View

10.

Crouthamel W . The effect of congestive heart failure on quinidine pharmacokinetics. Am Heart J. 1975; 90(3):335-9. DOI: 10.1016/0002-8703(75)90322-1. View

11.

Ueda C, Hirschfeld D, Scheinman M, Rowland M, Williamson B, Dzindzio B . Disposition kinetics of quinidine. Clin Pharmacol Ther. 1976; 19(1):30-6. DOI: 10.1002/cpt197619130. View

12.

Ueda C, Williamson B, Dzindzio B . Absolute quinidine bioavailability. Clin Pharmacol Ther. 1976; 20(3):260-5. DOI: 10.1002/cpt1976203260. View

13.

Sedman A, Wagner J . CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976; 65(7):1006-10. DOI: 10.1002/jps.2600650713. View

14.

Conrad K, Molk B, Chidsey C . Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation. 1977; 55(1):1-7. View

15.

Ueda C, Ballard B, Rowland M . Concentration-time effects of quinidine disposition kinetics in rhesus monkeys. J Pharmacol Exp Ther. 1977; 200(3):459-68. View

16.

Benowitz N, Meister W . Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet. 1976; 1(6):389-405. DOI: 10.2165/00003088-197601060-00001. View

17.

Greenblatt D, Pfeifer H, Ochs H, Franke K, MacLaughlin D, Smith T . Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther. 1977; 202(2):365-78. View

18.

Ueda C, Dzindzio B . Quinidine kinetics in congestive heart failure. Clin Pharmacol Ther. 1978; 23(2):158-64. DOI: 10.1002/cpt1978232158. View

19.

Kornhauser D, Wood A, Vestal R, Wilkinson G, Branch R, SHAND D . Biological determinants of propranolol disposition in man. Clin Pharmacol Ther. 1978; 23(2):165-74. DOI: 10.1002/cpt1978232165. View

20.

BEERMANN B . Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol. 1979; 7(6):579-83. PMC: 1429681. DOI: 10.1111/j.1365-2125.1979.tb04646.x. View